Tagrisso+Orpathys improved PFS & OS in EGFRm lung
AstraZeneca and HUTCHMED reported SAFFRON Phase III results: Tagrisso (osimertinib) plus Orpathys (savolitinib) improved progression-free survival and overall survival versus doublet platinum chemotherapy in 338 EGFR-mutated NSCLC patients with MET overexpression or amplification who progressed after Tagrisso. Safety matched known profiles, with no new findings. AstraZeneca said the combo aims for a biomarker-directed, all-oral option.
How this was made
The 30-second read
Why it matters
The article reports statistically significant and clinically meaningful improvements in both PFS and OS, with a safety profile consistent with prior knowledge and no new safety findings, and indicates intent to present at a medical meeting and share with regulators.
Market read
A positive global Phase III readout for an osimertinib plus savolitinib combination in MET-driven resistance after Tagrisso is a direct catalyst for AstraZeneca and HUTCHMED’s oncology pipeline expectations.
What to watch
Regulatory and payer adoption will depend on MET testing feasibility, cut-off robustness across assays (IHC/FISH), and whether the benefit persists in key clinical subgroups and after subsequent therapies.
Background
SAFFRON is a global Phase III trial in EGFR-mutated NSCLC with MET overexpression or amplification after progression on Tagrisso, comparing Tagrisso plus Orpathys versus doublet platinum chemotherapy.
Ticker impact
AstraZeneca says SAFFRON results show Tagrisso plus Orpathys improved PFS and OS versus platinum chemotherapy after progression on Tagrisso.
Likely positive near-term sentiment for AZN on expectations of global registration momentum, though magnitude depends on final OS/PFS magnitude and regulatory timelines.
The article is a first global Phase III showing statistically significant PFS and OS benefit in MET-driven resistance after osimertinib, with no new safety findings and explicit intent for global regulatory submissions.
HUTCHMED CEO states SAFFRON reinforces SACHI Phase III efficacy and provides evidence supporting global registrations for the Tagrisso plus Orpathys combination.
Potentially positive for HCM as investors price higher probability of broader approvals and commercial expansion for Orpathys in combination.
The text links SAFFRON outcomes to global registration plans and notes prior China approval support, which typically increases perceived regulatory and commercial upside for the partner asset.
Market effects
Reinforces the clinical viability of MET-targeted therapy added to osimertinib in EGFRm NSCLC after resistance, potentially shifting treatment sequencing expectations.
Could accelerate attention on China and global registration pathways for savolitinib-based combinations in EGFRm-MET resistance.
Global Phase III framing and planned regulatory discussions may influence broader EGFRm competitive landscape and biomarker testing urgency worldwide.
Counterpoint
Without the actual hazard ratios, absolute survival gains, and subgroup details, the market may overreact to headline “statistically significant and clinically meaningful” language.
Key entities
- drugTagrisso (osimertinib)
Third-generation EGFR TKI backbone therapy in EGFRm NSCLC, used after progression and with CNS activity.
- drugOrpathys (savolitinib)
Selective MET TKI jointly developed by AstraZeneca and HUTCHMED, targeting MET-driven resistance mechanisms.
- clinical_trialSAFFRON trial
Randomized, open-label global Phase III trial (338 patients) evaluating Orpathys added to Tagrisso versus platinum chemotherapy after progression on Tagrisso.
- clinical_trialSACHI Phase III
Earlier Phase III trial supporting Orpathys plus Tagrisso approval in China for MET amplification after EGFR-TKI progression.
